16S rRNA amplicon sequencing of diabetic UCD-T2DM rats undergoing leptin treatment
Preclinical evidence suggests that gut microbial dysbiosis contributes to the progression of type 2 diabetes (T2DM). Alterations in the gut microbiome, energy metabolism, and barrier function have been observed in individuals with obesity and insulin resistance. However, it remains unclear whether therapeutic interventions can reverse these disruptions. This study aimed to evaluate whether improvements of glucose homeostasis resulting from leptin administration can lead to changes in gut microbial communities in diabetic male UC Davis Type 2 Diabetic Mellitus (UCD-T2DM) rats.